We have discovered that non-neoplastic rat tissues (uterus, liver, spleen, serum) contain a compound which inhibits 3H-estradiol binding (type II sites) in rat uterine nuclei. Since elevated nuclear levels of type II sites are highly correlated with increased cell proliferation in normal (uterus) and malignant (mouse mammary tumors and human breast cancer) tissues, we feel this inhibitor might be an endogenous anti-proliferative agent. Preliminary studies support this concept in that partially purified preparations of this inhibitor block the growth of normal and malignant cells in culture. Furthermore, estrogen-induced rat mammary tumors are deficient in this inhibitor activity which is consistent with the rapid rate of proliferation in these cell populations.
The specific aims of this proposal are to purify this inhibitor to homogeneity and structurally identify the compound(s) by mass spectrometry, nuclear magnetic resonance studies and infra-red spectrometry. In addition we plan to study the interaction of the pure material (purchased; synthesized or prepared from rat liver) with nuclear type II estrogen binding sites (association and dissociation rates; competitive vs. non-competitive inhibition) in normal (rat uterus) and malignant (rat and mouse mammary tumors) tissues. These studies should point out any defects in the ability of nuclear type II sites in malignant tissues to recognize this inhibitor. The effects of pure inhibitor on cell proliferation (cell growth; rate of entry and fraction of cells in S-phase) will be evaluated (rat uterine cells; estrogen-induced rat mammary tumor cells; MCF-7 Human Breast Cancer cells) and these changes correlated to the effects of the inhibitor on nuclear type II estrogen binding sites in these cell populations. Since tumors appear to be deficient in this inhibitor activity, studies will be done to determine whether tumor cells (as described above) or microsomal fractions from estrogen-induced rat mammary tumors will metabolize this inhibitor to an """"""""inactive"""""""" form. The results of these experiments may provide a new approach to studies involving the regulation of cell proliferation in normal and neoplastic cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA035480-03
Application #
3173046
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1983-08-01
Project End
1986-07-31
Budget Start
1985-08-01
Budget End
1986-07-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
Schools of Medicine
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Markaverich, Barry M; Shoulars, Kevin; Rodriguez, Mary Ann (2011) Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells. Int J Biomed Sci 7:101-111
Markaverich, Barry M; Vijjeswarapu, Mary; Shoulars, Kevin et al. (2010) Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells. J Steroid Biochem Mol Biol 122:219-31
Shoulars, Kevin; Rodriguez, Mary Ann; Thompson, Trellis et al. (2010) Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin. J Steroid Biochem Mol Biol 118:41-50
Shoulars, Kevin; Rodriguez, Mary Ann; Thompson, Trellis et al. (2008) Regulation of the nitric oxide pathway genes by tetrahydrofurandiols: microarray analysis of MCF-7 human breast cancer cells. Cancer Lett 264:265-73
Markaverich, Barry M; Crowley, Jan; Rodriquez, Mary et al. (2007) Tetrahydrofurandiol stimulation of phospholipase A2, lipoxygenase, and cyclooxygenase gene expression and MCF-7 human breast cancer cell proliferation. Environ Health Perspect 115:1727-31
Markaverich, Barry M; Alejandro, Mary; Thompson, Trellis et al. (2007) Tetrahydrofurandiols (THF-diols), leukotoxindiols (LTX-diols), and endocrine disruption in rats. Environ Health Perspect 115:702-8
Markaverich, Barry M; Shoulars, Kevin; Alejandro, Mary-Ann (2006) Nuclear type II [3H]estradiol binding site ligands: inhibition of ER-positive and ER-negative cell proliferation and c-Myc and cyclin D1 gene expression. Steroids 71:865-74
Shoulars, Kevin; Rodriguez, Mary Ann; Crowley, Jan et al. (2006) Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4. J Steroid Biochem Mol Biol 99:1-8
Shoulars, Kevin; Rodrigues, Mary Ann; Crowley, Jan R et al. (2005) Nuclear type II [3H]estradiol binding sites: a histone H3-H4 complex. J Steroid Biochem Mol Biol 96:19-30
Markaverich, Barry M; Crowley, Jan R; Alejandro, Mary A et al. (2005) Leukotoxin diols from ground corncob bedding disrupt estrous cyclicity in rats and stimulate MCF-7 breast cancer cell proliferation. Environ Health Perspect 113:1698-704

Showing the most recent 10 out of 25 publications